StreetInsider.com News Articles

Form 8-K Cartesian Therapeutics, For: Jun 12

Wed, 17 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26659719.html

Form 8-K Cartesian Therapeutics, For: Jun 12

Wed, 17 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260617/26659719.html

Cartesian Therapeutics Announces New Employment Inducement Grant

Fri, 12 Jun 2026 16:05:00 -0400

FREDERICK, Md., June 12, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of an inducement award to one new employee. On June 8, 2026, the Company issued to this employee an option to purchase an aggregate of 6,100 shares of the Company’s common stock with an exercise price of $5.86, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company’s Amended and

Cartesian Therapeutics Announces New Employment Inducement Grant

Fri, 12 Jun 2026 16:05:00 -0400

Cartesian Therapeutics Announces New Employment Inducement Grant

Fri, 12 Jun 2026 16:05:00 -0400

Cartesian Therapeutics Announces New Employment Inducement Grant

Fri, 12 Jun 2026 16:05:00 -0400

Form 144 Cartesian Therapeutics, Filed by: Miljkovic Milos

Tue, 09 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260609/26623840.html

Form 144 Cartesian Therapeutics, Filed by: Miljkovic Milos

Tue, 09 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260609/26623840.html

Form 8-K Cartesian Therapeutics, For: Jun 09

Tue, 09 Jun 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260609/26620191.html

Form 8-K Cartesian Therapeutics, For: Jun 09

Tue, 09 Jun 2026 07:17:00 -0400

si-local-file:///var/storage/secattach/20260609/26620191.html

Cartesian Therapeutics partners with WestGene for in vivo CAR-T development

Tue, 09 Jun 2026 07:01:51 -0400

Cartesian Therapeutics Inc. (NASDAQ: RNAC) announced a strategic licensing agreement with WestGene Biopharma Co. Ltd. to develop in vivo chimeric antigen receptor T-cell therapies for autoimmune diseases.

The partnership combines WestGene's targeted lipid nanoparticle platform with Cartesian's mRNA payload from its Descartes-08 program. The collaboration aims to eliminate the ex vivo manufacturing step required in traditional CAR-T therapy production.

WestGene has previously conducted clinical studies using mRNA CAR-T constructs delivered through its targeted lipid nanoparticle platform in oncology and autoimmune diseases. The company reported no dose-limiting toxicities, serious adverse events, or significant immune-related complications across multiple dosing regimens, including up to 14

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Tue, 09 Jun 2026 07:00:00 -0400

WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation

Plans to advance multiple Cartesian-owned, internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed TCE as part of expanding mRNA payload portfolio

Clinical trial expected to initiate in 2H 2026 using mRNA payload from Descartes-08 combined with WestGene’s LNP platform in patients with MG; Clinical data expected in 1H 2027

FREDERICK, Md., June 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company” or “Cartesian”), a late

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Tue, 09 Jun 2026 07:00:00 -0400

WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation

Plans to advance multiple Cartesian-owned, internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed TCE as part of expanding mRNA payload portfolio

Clinical trial expected to initiate in 2H 2026 using mRNA payload from Descartes-08 combined with WestGene’s LNP platform in patients with MG; Clinical data expected in 1H 2027

FREDERICK, Md., June 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company” or “Cartesian”), a late

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Tue, 09 Jun 2026 07:00:00 -0400

WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation

Plans to advance multiple Cartesian-owned, internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed TCE as part of expanding mRNA payload portfolio

Clinical trial expected to initiate in 2H 2026 using mRNA payload from Descartes-08 combined with WestGene’s LNP platform in patients with MG; Clinical data expected in 1H 2027

FREDERICK, Md., June 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company” or “Cartesian”), a late

Cartesian Therapeutics Announces Strategic Licensing Agreement with WestGene Biopharma to Accelerate the Development of In Vivo CAR-T Platform in Autoimmune Diseases

Tue, 09 Jun 2026 07:00:00 -0400

WestGene’s established targeted LNP platform combined with Cartesian’s mRNA payload from Descartes-08 integrates two independently, clinically tested technologies for rapid clinical translation

Plans to advance multiple Cartesian-owned, internally developed next-generation anti-BCMA CAR constructs and a BCMA-directed TCE as part of expanding mRNA payload portfolio

Clinical trial expected to initiate in 2H 2026 using mRNA payload from Descartes-08 combined with WestGene’s LNP platform in patients with MG; Clinical data expected in 1H 2027

FREDERICK, Md., June 09, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company” or “Cartesian”), a late

Form 144 Cartesian Therapeutics, Filed by: Miljkovic Milos

Tue, 02 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260602/26591635.html

Form 144 Cartesian Therapeutics, Filed by: Miljkovic Milos

Tue, 02 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260602/26591635.html

Mizuho on Cartesian Therapeutics (RNAC): 'We believe the potential of Descartes-08 remains underappreciated'

Tue, 26 May 2026 10:48:12 -0400

Mizuho analyst Uy Ear reiterated an Outperform rating and $40.00 price target on Cartesian Therapeutics (NASDAQ: RNAC).

The analyst comments "This morning, Cartesian announced that it has secured a non-dilutive credit facility of up to $150M with K2 HealthVentures. Cartesian's initial $50M draw extends its cash runway from mid-2027 into 2028 and provide funding for pre-commercial activities for Descartes-08 in myasthenia gravis. Additionally, Cartesian provided its mid-year update, moving up the top-line readout timeline for its registrational Phase 3 AURORA trial in myasthenia gravis from mid-2027 to 1Q27 -- suggesting that enrollment is likely near completion -- and expecting potential BLA

Form 8-K Cartesian Therapeutics, For: May 22

Tue, 26 May 2026 07:09:00 -0400

si-local-file:///var/storage/secattach/20260526/26545773.html

Form 8-K Cartesian Therapeutics, For: May 22

Tue, 26 May 2026 07:09:00 -0400

si-local-file:///var/storage/secattach/20260526/26545773.html

Cartesian Therapeutics secures $150 million credit facility from K2 HealthVentures